MediWound Ltd. announced Q1 2026 revenue of $1.5 million, down from $4 million in Q1 2025 due to timing of BARDA-related revenues and shipment delays. The company is progressing its EscharEx Phase III VALUE trial for chronic wound treatment, with enrollment expected to complete by Q1 2027. NexoBrid adoption in the U.S. is growing, supported by a new BARDA contract valued up to $197 million, expected to drive revenue growth in the second half of 2026. MediWound reaffirmed its full-year 2026 revenue guidance of $24-26 million, focusing on regulatory approvals and expanded manufacturing capacity.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
